The Single-Gene Illusion: Warmblood Genetic Testing

A pre-purchase exam has a rhythm to it: flexions, a jog on hard ground, radiographs read against the light, and then, increasingly, a hair sample pulled from the mane and dropped into a prepaid envelope. The DNA panel has become as routine as the vet check itself for warmblood buyers, and it feels like the more modern half of the exam, the part that promises certainty instead of an educated guess. It rarely delivers on that promise, and a survey published this year out of the University of California, Davis explains exactly why.

What Owners Actually Want to Know

Researchers led by Michael J. Mienaltowski in the Department of Animal Science at UC Davis surveyed 412 horse owners and enthusiasts across 44 states between March and October 2024, publishing the results in the Journal of Equine Veterinary Science this past spring. Warmblood owners made up 68.2 percent of respondents, by far the largest single group, ahead of Thoroughbred owners at 19.4 percent. When asked which health concerns they most wanted genetic testing to address, respondents ranked arthritis, metabolic disorders, tendon and ligament injuries, and ulcers alongside laminitis, colic, and behavior and temperament.

Almost none of that list can currently be answered by a DNA test, and the researchers said as much: the survey's own conclusion calls for continued owner education and further development of testing tools, an acknowledgment that the tools available today do not match what buyers are asking them to do.

The Test That Exists

The genetic test warmblood buyers actually get is built for a different kind of disease. Warmblood Fragile Foal Syndrome, the condition that produces foals with skin so fragile it tears on contact, traces to a single mutation at one position on the horse's PLOD1 gene, inherited in a clean recessive pattern. That single-mutation biology is precisely why a lab can sequence it and hand back a definitive carrier status, and why the test exists commercially at all, sold under license from Cornell University. Panels sold by companies like Etalon Diagnostics bundle WFFS in with a few dozen other single-gene conditions, including Hoof Wall Separation Disease and Hydrocephalus. Etalon is upfront that several of its other offerings sit in what it calls a "discovery stage," where a genetic association has been proposed but not yet confirmed by independent research, which is a more honest position than the industry as a whole tends to take.

A single-gene test can only be as precise as the biology behind it, and most of what shortens a hunter or jumper's career is not single-gene biology at all.

The Problem Is the Biology, Not the Lab

Osteochondrosis is the clearest illustration. It is not on any owner's top-priority list by name, but it sits underneath the joint problems and soundness issues that are, and warmblood breed registries have spent four decades trying to breed it out. A 2008 study of 1,231 clinically sound Dutch Warmblood horses presented for pre-purchase examination found radiographic evidence of osteochondrosis in 44.3 percent of them, horses their owners judged healthy enough to sell as sound. The Royal Dutch Warmblood Studbook has rejected any stallion candidate showing even minor radiographic signs of tarsocrural osteochondrosis since 1984, and the condition's prevalence has not meaningfully declined since.

A 2023 study from the University of Veterinary Medicine Hannover, examining 446 Hanoverian warmbloods, found that osteochondrosis is genuinely heritable, and that the degree of heritability differs considerably from one joint to the next, higher in the hock than in the stifle. But the genetic signal behind it does not trace to one location. A separate genome-wide association study of Dutch Warmblood horses found associated loci on two entirely different chromosomes, three and ten, and other work on the condition across breeds has turned up significant regions scattered across still more. Nutrition, growth rate, and trauma all shape whether a genetically susceptible horse develops the disease at all. There is no PLOD1 equivalent waiting to be found here. The condition is polygenic and environmentally modified by nature, which means no single marker, however well validated, will ever tell a buyer what decades of KWPN selection pressure has not been able to eliminate.

The same logic holds for arthritis, metabolic disorders, and tendon and ligament injury, the conditions owners actually asked about. Equine metabolic syndrome makes the point well: a 2019 genome-wide association study published in the journal Genes found 303 associated genomic regions in Welsh ponies and 142 in Morgan horses, and a candidate gene identified in Arabian horses in earlier research has not held up as a marker in other breeds. Each of these conditions involves the interaction of many genes with training load, footing, farriery, and age. A test built to catch one dominant or recessive mutation has no mechanism for capturing that.

Where the Real Progress Is Happening

The more honest genetic tools now emerging are built at the population level, not the individual one. In February, the International Association for the Future of Horse Breeding, a joint project of Germany's major breeding societies, launched a genomic breeding value database that pools multi-breed data to estimate breeding values for conformation, performance, and health traits across a population of stallions. It is a serious infrastructure project, and it is explicitly a breeding tool for registries and stallion owners making mating decisions across thousands of horses, not a diagnostic report a buyer can run on the gelding standing in the aisle. Population-level genomics can shift the odds for a breed over a generation. It cannot tell one buyer, about one horse, whether that horse's hocks will hold up through a hunter derby career.

None of this makes genetic testing worthless. A WFFS result is a real answer to a real question, and it is worth having before breeding a mare. It cannot substitute for the harder, older forms of due diligence, and the industry's marketing has been content to let buyers believe otherwise. A $149 hair-sample panel feels more modern than a set of X-rays, but it answers a much narrower question. Until the science catches up to what the UC Davis survey shows buyers actually want, the radiograph and the flexion test remain the tools doing the real work, and no amount of laboratory polish should be allowed to suggest otherwise.